CVS Corporation company logo

# RNN 2nd Gen Model CVS Corporation Drug stores & proprietary stores

Prediction models:
72.34% successful of 47 deals
$ 54.95 Last close price
at 25-mar-2019

CVS

Model's trade recommendations 16.53% Return for period

-1.95% Annual return

$66.90B Market Cap

β 1.02  

CVS

Model (following trade recommendations)

CVS

Underlying stock

S&P 500

Index
Return for period 16.53%
-8.48%
1.78%
52wk return 2.28%
-7.92%
16.82%
52wk Range
52.36—80.80
2000.54—2399.63
Sortino ratio -0.12
Sharpe ratio -0.11
Norm. RMSE 1.10%
Downside risk 11.35%
Volatility 0.00%
  • 2.00 (3.03%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.

Industry sector: Retail/Wholesale

Sector classification: Drug stores & proprietary stores

Deep Learning based analysis and prediction model for CVS Corporation (CVS) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CVS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a regular basis.

Float 1009M
P/E 10.58
Shares Outstanding 1015M
% Held by Insiders 0.53%
% Held by Institutions 84.03%
EPS (last reported FY) $5.90
EPS (last reported Q) $1.48
EPS, estimated (last reported Q) $1.39
Total revenues $185 B
Net income $7 B